Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Among authors: litvinov d. Leukemia. 2022 May;36(5):1382-1385. doi: 10.1038/s41375-022-01542-z. Epub 2022 Mar 23. Leukemia. 2022. PMID: 35322171 No abstract available.
Efficacy and toxicity of dexamethasone vs methylprednisolone-long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002.
Karachunskiy A, Roumiantseva J, Lagoiko S, Bührer C, Tallen G, Aleinikova O, Bydanov O, Korepanova N, Bajdun L, Nasedkina T, von Stackelberg A, Novichkova G, Maschan A, Litvinov D, Myakova N, Ponomareva N, Kondratchik K, Fechina L, Streneva O, Judina N, Scharapova G, Shamardina A, Gerbek I, Shapochnik A, Rumjanzew A, Henze G; ALL-MB study group. Karachunskiy A, et al. Among authors: litvinov d. Leukemia. 2015 Sep;29(9):1955-8. doi: 10.1038/leu.2015.63. Epub 2015 Mar 9. Leukemia. 2015. PMID: 25748686 No abstract available.
Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002.
Karachunskiy A, Tallen G, Roumiantseva J, Lagoiko S, Chervova A, von Stackelberg A, Aleinikova O, Bydanov O, Bajdun L, Nasedkina T, Korepanova N, Kuznetsov S, Novichkova G, Goroshkova M, Litvinov D, Myakova N, Ponomareva N, Inyushkina E, Kondratchik K, Abugova J, Fechina L, Arakaev O, Karelin A, Lebedev V, Judina N, Scharapova G, Spichak I, Shamardina A, Ryskal O, Shapochnik A, Rumjanzew A, Boos J, Henze G; ALL-MB study group. Karachunskiy A, et al. Among authors: litvinov d. J Cancer Res Clin Oncol. 2019 Apr;145(4):1001-1012. doi: 10.1007/s00432-019-02854-x. Epub 2019 Mar 6. J Cancer Res Clin Oncol. 2019. PMID: 30840197 Free PMC article. Clinical Trial.
Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia.
Goronkova O, Novichkova G, Salimova T, Kalinina I, Baidildina D, Petrova U, Antonova K, Sadovskaya M, Suntsova E, Evseev D, Matveev V, Venyov D, Khachatryan L, Litvinov D, Pshonkin A, Ovsyannikova G, Kotskaya N, Gobadze D, Olshanskaya Y, Popov A, Raykina E, Mironenko O, Voronin K, Purbueva B, Boichenko E, Dinikina Y, Guseynova E, Sherstnev D, Kalinina E, Mezentsev S, Streneva O, Yudina N, Plaksina O, Erega E, Maschan M, Maschan A. Goronkova O, et al. Among authors: litvinov d. Blood Adv. 2023 Mar 28;7(6):953-962. doi: 10.1182/bloodadvances.2021006716. Blood Adv. 2023. PMID: 35446936 Free PMC article. Clinical Trial.
One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Among authors: litvinov d. J Cancer Res Clin Oncol. 2023 Jul;149(8):4629-4637. doi: 10.1007/s00432-022-04378-3. Epub 2022 Sep 28. J Cancer Res Clin Oncol. 2023. PMID: 36169717
A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Among authors: litvinov d. Leuk Res. 2022 Dec;123:106982. doi: 10.1016/j.leukres.2022.106982. Epub 2022 Oct 22. Leuk Res. 2022. PMID: 36332292 No abstract available.
Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 2008.
Popov A, Henze G, Roumiantseva J, Budanov O, Verzhbitskaya T, Boyakova E, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Ponomareva N, Novichkova G, Fechina L, Karachunskiy A. Popov A, et al. Among authors: litvinov d. Leuk Res. 2023 Feb;125:106998. doi: 10.1016/j.leukres.2022.106998. Epub 2022 Dec 16. Leuk Res. 2023. PMID: 36566537 No abstract available.
A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Among authors: litvinov d. Pediatr Blood Cancer. 2023 Jun;70(6):e30295. doi: 10.1002/pbc.30295. Epub 2023 Mar 28. Pediatr Blood Cancer. 2023. PMID: 36975157
A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALL.
Popov A, Henze G, Roumiantseva J, Bydanov O, Belevtsev M, Verzhbitskaya T, Movchan L, Tsaur G, Lagoyko S, Zharikova L, Myakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Among authors: litvinov d. Cancers (Basel). 2023 Nov 23;15(23):5547. doi: 10.3390/cancers15235547. Cancers (Basel). 2023. PMID: 38067249 Free PMC article.
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
Popov A, Henze G, Tsaur G, Budanov O, Roumiantseva J, Belevtsev M, Verzhbitskaya T, Movchan L, Lagoyko S, Zharikova L, Olshanskaya Y, Riger T, Valochnik A, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Aleinikova O, Fechina L, Karachunskiy A. Popov A, et al. Among authors: litvinov d. Cancer Med. 2024 Apr;13(8):e7172. doi: 10.1002/cam4.7172. Cancer Med. 2024. PMID: 38651186 Free PMC article.
103 results